Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pliant Therapeutics Inc (NQ: PLRX ) 11.31 +0.14 (+1.25%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Pliant Therapeutics Inc < Previous 1 2 3 Next > Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer September 24, 2024 From Aligos Therapeutics Via GlobeNewswire Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024 September 10, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Events August 28, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024 August 26, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results August 07, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference August 06, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures July 15, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors June 13, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 12, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ June 06, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference May 21, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis May 14, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™ May 07, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results May 06, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Events May 01, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Events April 02, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference March 27, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis March 12, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results February 27, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Conferences February 26, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Events February 07, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis February 04, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis November 13, 2023 INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results November 09, 2023 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Conferences November 08, 2023 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1 November 06, 2023 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer October 31, 2023 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 October 19, 2023 Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer October 16, 2023 From Pliant Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.